Component
Systemic availability of colon-delivered butyrate in humans
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In 12 healthy subjects receiving isotope-labeled SCFAs in colon-release capsules, systemic availability was approximately 2% for butyrate, compared with 9% propionate and 36% acetate.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_access
- Primary abstract
- experimental_model
- Human stable-isotope pharmacokinetic study.
- limitations
- Specific to colonic delivery and study conditions; does not quantify oral immediate-release, rectal or injected exposure.
- nutrient_topic
- Butyrate collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Butyrate
- plain_language
- Most colon-delivered butyrate did not reach the general circulation unchanged.
- primary_references
- Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. · 2017 · https://pubmed.ncbi.nlm.nih.gov/27510655/ · DOI 10.1113/JP272613
- trigger_kind
- biomarker_context Imported condition classification; unverified.
Butyrate: microbial production, fuel use, signaling and nutrient interactions (2026-09-19) · lines 142–148
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Human stable-isotope pharmacokinetic study. · source_derived_draft · unverified_draft
## butyrate-systemic-availability Most colon-delivered butyrate did not reach the general circulation unchanged. In 12 healthy subjects receiving isotope-labeled SCFAs in colon-release capsules, systemic availability was approximately 2% for butyrate, compared with 9% propionate and 36% acetate. Model: Human stable-isotope pharmacokinetic study. Limitations: Specific to colonic delivery and study conditions; does not quantify oral immediate-release, rectal or injected exposure. Evidence access: Primary abstract Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. · 2017 · https://pubmed.ncbi.nlm.nih.gov/27510655/ · DOI 10.1113/JP272613
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.